JPH10503479A - 中枢神経系ミエリン再形成を促進するモノクローナル抗体 - Google Patents
中枢神経系ミエリン再形成を促進するモノクローナル抗体Info
- Publication number
- JPH10503479A JPH10503479A JP7528392A JP52839295A JPH10503479A JP H10503479 A JPH10503479 A JP H10503479A JP 7528392 A JP7528392 A JP 7528392A JP 52839295 A JP52839295 A JP 52839295A JP H10503479 A JPH10503479 A JP H10503479A
- Authority
- JP
- Japan
- Prior art keywords
- monoclonal antibody
- cells
- nervous system
- culture
- central nervous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
- Y10S530/809—Fused cells, e.g. hybridoma
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/839—Nerves; brain
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/863—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgM
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.哺乳動物において中枢神経系軸索のミエリン再形成を刺激する方法であって 、ATCC受託番号第 CRL 11627号を有するハイブリドーマによって産生された モノクローナル抗体の有効量を該哺乳動物に投与することを含む方法。 2.該投与方法が静脈内投与である請求項1記載の方法。 3.該投与方法が腹腔内投与である請求項1記載の方法。 4.前記モノクローナル抗体の投与量が約0.5mg/kg〜約400 mg/kgである請 求項1記載の方法。 5.哺乳動物において中枢神経系軸索内のグリア細胞の増殖を刺激する方法であ って、ATCC受託番号第 CRL 11627号を有するハイブリドーマによって産生さ れたモノクローナル抗体の有効量を該哺乳動物に投与することを含む方法。 6.該投与方法が静脈内投与である請求項5記載の方法。 7.該投与方法が腹腔内投与である請求項5記載の方法。 8.前記モノクローナル抗体の投与量が約0.5mg/kg〜約400 mg/kgである請 求項5記載の方法。 9.哺乳動物において中枢神経系の脱髄性疾患を治療する方法であって、ATC C受託番号第 CRL 11627号を有するハイブリドーマによって産生されたモノクロ ーナル抗体の有効量を前記哺乳動物に投与して前記哺乳動物の中枢神経系軸索の ミエリン再形成を促進することを含む方法。 10.前記哺乳動物が多発性硬化症に罹患したヒトであるか又はウイルス性脱髄性 疾患又は中枢神経系の後神経性疾患に罹患したヒト又は家畜である請求項9記載 の方法。 11.該投与方法が静脈内投与である請求項9記載の方法。 12.該投与方法が腹腔内投与である請求項9記載の方法。 13.前記モノクローナル抗体の投与量が約0.5mg/kg〜約400 mg/kgである請 求項9記載の方法。 14.前記哺乳動物がサイラーマウス脳脊髄炎ウイルスのDA株に感染したマウス である請求項9記載の方法。 15.中枢神経系軸索のミエリン再形成を刺激することができるモノクローナル抗 体を産生するハイブリドーマATCC受託番号第 CRL 11627号を含むハイブリド ーマ。 16.グリア細胞を生産する試験管内方法であって、 a)グリア細胞を細胞増殖に十分な条件下で培養して、グリア細胞培養物を生 産する工程; b)該グリア細胞にATCC受託番号第 CRL 11627号を有するハイブリドーマ によって産生されたモノクローナル抗体の有効量を導入して、モノクローナル抗 体処理グリア細胞培養物を生産する工程; c)工程b)の培養物をモノクローナル抗体処理細胞の増殖に十分な条件下に 維持する工程;及び d)該細胞を培養から収集してグリア細胞を得る工程; を含む方法。 17.請求項16記載の方法によって得られたグリア細胞。 18.混合細胞培養物からのグリア細胞の増殖を刺激する試験管内方法であって、 a)グリア細胞を含む混合細胞培養物を細胞増殖に十分な条件下で培養する工 程; b)該混合培養物にATCC受託番号第 CRL 11627号を有するハイブリドーマ によって産生されたモノクローナル抗体の有効量を導入して、モノクローナル抗 体処理混合培養物を生産する工程; c)工程b)の培養物をモノクローナル抗体処理細胞の増殖に十分な条件下に 維持して、該混合培養物内のグリア細胞の増殖を生じる工程; d)該グリア細胞を該混合培養物から収集する工程; を含む方法。 19.該混合培養物がラット視神経から得られる請求項18記載の方法。 20.該混合培養物がラット脳から得られる請求項18記載の方法。 21.請求項18記載の方法によって得られたグリア細胞。 22.哺乳動物において中枢神経系軸索のミエリン再形成を刺激する方法であって 、 a)グリア細胞を細胞増殖に十分な条件下で培養して、グリア細胞培養物を生 産する工程; b)該グリア細胞培養物にATCC受託番号第 CRL 11627号を有するハイブリ ドーマによって産生されたモノクローナル抗体の有効量を導入して、モノクロー ナル抗体処理グリア細胞培養物を生産する工程; c)工程b)の培養物をモノクローナル抗体処理細胞の増殖に十分な条件下に 維持する工程; d)該モノクローナル抗体処理細胞を培養から収集してグリア細胞を得る工程 ; e)工程d)で得られた該グリア細胞を該哺乳動物の中枢神経系に導入して、 中枢神経系軸索のミエリン再形成を刺激する工程; を含む方法。 23.請求項15記載のハイブリドーマから生産可能なモノクローナル抗体。 24.治療に使用するための請求項23記載のモノクローナル抗体。 25.中枢神経系軸索のミエリン再形成を刺激する薬剤の製造のために使用される 請求項23記載のモノクローナル抗体の使用。 26.中枢神経系軸索内のグリア細胞の増殖を刺激する薬剤の製造のために使用さ れる請求項23記載のモノクローナル抗体の使用。 27.中枢神経系の脱髄性疾患、例えば、多発性硬化症、ウイルス性脱髄性疾患又 は中枢神経系の後神経性疾患を治療する薬剤の製造のために使用される請求項23 記載のモノクローナル抗体の使用。 28.該薬剤が、サイラーマウス脳脊髄炎ウイルスのDA株に感染したマウスを治 療するために使用される請求項27記載の使用。 29.該投与方法が静脈内投与又は腹腔内投与である請求項25〜27のいずれか1項 に記載の使用。 30.前記モノクローナル抗体の投与量が約0.5mg/kg〜約400 mg/kgである請 求項25〜28記載の使用。 31.哺乳動物において中枢神経系軸索のミエリン再形成を刺激するグリア細胞の 調製方法であって、 a)グリア細胞を細胞増殖に十分な条件下で培養して、グリア細胞培養物を生 産する工程; b)該グリア細胞培養物にATCC受託番号第 CRL 11627号を有するハイブリ ドーマによって産生されたモノクローナル抗体の有効量を導入して、モノクロー ナル抗体処理クリア細胞培養物を生産する工程; c)工程b)の培養物を培養物からのモノクローナル抗体処理細胞の増殖に十 分な条件下に維持して、グリア細胞を得る工程; を含む方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/236,520 | 1994-04-29 | ||
US08/236,520 US5591629A (en) | 1994-04-29 | 1994-04-29 | Monoclonal antibodies which promote central nervous system remyelination |
PCT/US1995/005262 WO1995030004A1 (en) | 1994-04-29 | 1995-04-27 | Monoclonal antibodies which promote central nervous system remyelination |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH10503479A true JPH10503479A (ja) | 1998-03-31 |
JP3789472B2 JP3789472B2 (ja) | 2006-06-21 |
Family
ID=22889861
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52839295A Expired - Lifetime JP3789472B2 (ja) | 1994-04-29 | 1995-04-27 | 中枢神経系ミエリン再形成を促進するモノクローナル抗体 |
Country Status (13)
Country | Link |
---|---|
US (1) | US5591629A (ja) |
EP (1) | EP0801679B1 (ja) |
JP (1) | JP3789472B2 (ja) |
KR (1) | KR100406551B1 (ja) |
CN (1) | CN1152939A (ja) |
AT (1) | ATE290597T1 (ja) |
AU (1) | AU699724B2 (ja) |
CA (1) | CA2188919C (ja) |
DE (1) | DE69534064T2 (ja) |
ES (1) | ES2238073T3 (ja) |
MX (1) | MX9605257A (ja) |
NZ (1) | NZ284757A (ja) |
WO (1) | WO1995030004A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004516807A (ja) * | 2000-05-10 | 2004-06-10 | メイヨ ファンデーション フォア メディカル エディケイション アンド リサーチ | 髄鞘再形成を誘導する能力を有するヒトIgM抗体、および、特に中枢神経系における、その診断使用及び治療使用 |
JP2007514163A (ja) * | 2003-12-12 | 2007-05-31 | スリーエム イノベイティブ プロパティズ カンパニー | 可変性バルブ装置および方法 |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7473423B2 (en) * | 1994-04-29 | 2009-01-06 | Mayo Foundation For Medical Education And Research | Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system |
AU4373197A (en) * | 1996-09-19 | 1998-04-14 | Diagnocure Inc. | Recombinant single chain antibodies directed against the gp54 cancer marker, composition comprising same and use thereof |
US7541034B1 (en) * | 1997-03-20 | 2009-06-02 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant antibodies and immunoconjugates targeted to CD-22 bearing cells and tumors |
EP1098902A4 (en) | 1998-07-23 | 2002-07-24 | Yeda Res & Dev | TREATMENT OF AUTOIMMUNE DISEASES BY COPOLYMER 1 AND SIMILAR COPOLYMERS AND PEPTIDES |
ES2527760T3 (es) * | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
US6800287B2 (en) | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
US7022663B2 (en) * | 2000-02-18 | 2006-04-04 | Yeda Research And Development Co., Ltd. | Oral, nasal and pulmonary dosage formulations of copolymer 1 |
US20020077278A1 (en) * | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
WO2002076503A1 (en) * | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
MXPA04005433A (es) | 2001-12-04 | 2004-10-11 | Teva Pharma | Proceso para la medicion de la potencia de acetato de glatiramero. |
DE10212108A1 (de) * | 2002-03-13 | 2003-10-02 | Tegenero Ag | Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung |
US7052694B2 (en) * | 2002-07-16 | 2006-05-30 | Mayo Foundation For Medical Education And Research | Dendritic cell potentiation |
US8460665B2 (en) * | 2003-05-16 | 2013-06-11 | Mayo Foundation For Medical Education And Research | Compositions and methods including a recombinant human MAB that promotes CNS remyelination |
US7582261B2 (en) * | 2003-11-18 | 2009-09-01 | Sharp Kabuhsiki Kaisha | Electricity supplying device, electricity supplying apparatus, sample detection device, and sample detection apparatus |
US7501119B2 (en) * | 2004-06-30 | 2009-03-10 | Mayo Foundation For Medical Education And Research | Methods and molecules for modulating an immune response |
US20060099203A1 (en) * | 2004-11-05 | 2006-05-11 | Pease Larry R | B7-DC binding antibody |
US8445008B2 (en) * | 2008-10-17 | 2013-05-21 | Medtronic, Inc. | Reduction of infection associated with medical device |
US9150867B2 (en) | 2011-04-28 | 2015-10-06 | Mayo Foundation For Medical Education And Research | DNA aptamers for promoting remyelination |
MD20180107A2 (ro) | 2013-03-18 | 2019-06-30 | Biocerox Products B.V. | Anticorpi anti-CD134 (OX40) umanizaţi şi utilizarea acestora |
US11999778B2 (en) | 2016-05-13 | 2024-06-04 | The Board Of Regents Of The University Of Texas System | VH4 antibodies and compositions comprising the same |
WO2019028182A2 (en) * | 2017-08-01 | 2019-02-07 | Remd Biotherapeutics, Inc. | TREATMENT OF CANCER USING ANTIBODIES BINDING TO THE HUMAN CD134 RECEPTOR (OX40) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU8864691A (en) * | 1990-09-07 | 1992-03-30 | Regents Of The University Of California, The | Glial antiproliferative proteins |
-
1994
- 1994-04-29 US US08/236,520 patent/US5591629A/en not_active Expired - Lifetime
-
1995
- 1995-04-27 AU AU23990/95A patent/AU699724B2/en not_active Expired
- 1995-04-27 CN CN95193822A patent/CN1152939A/zh active Pending
- 1995-04-27 NZ NZ284757A patent/NZ284757A/en unknown
- 1995-04-27 WO PCT/US1995/005262 patent/WO1995030004A1/en active IP Right Grant
- 1995-04-27 DE DE69534064T patent/DE69534064T2/de not_active Expired - Lifetime
- 1995-04-27 MX MX9605257A patent/MX9605257A/es unknown
- 1995-04-27 EP EP95917195A patent/EP0801679B1/en not_active Expired - Lifetime
- 1995-04-27 ES ES95917195T patent/ES2238073T3/es not_active Expired - Lifetime
- 1995-04-27 CA CA2188919A patent/CA2188919C/en not_active Expired - Lifetime
- 1995-04-27 JP JP52839295A patent/JP3789472B2/ja not_active Expired - Lifetime
- 1995-04-27 KR KR1019960706075A patent/KR100406551B1/ko not_active IP Right Cessation
- 1995-04-27 AT AT95917195T patent/ATE290597T1/de not_active IP Right Cessation
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004516807A (ja) * | 2000-05-10 | 2004-06-10 | メイヨ ファンデーション フォア メディカル エディケイション アンド リサーチ | 髄鞘再形成を誘導する能力を有するヒトIgM抗体、および、特に中枢神経系における、その診断使用及び治療使用 |
JP2013059318A (ja) * | 2000-05-10 | 2013-04-04 | Mayo Foundation For Medical Education & Research | 髄鞘再形成を誘導する能力を有するヒトIgM抗体、および、特に中枢神経系における、その診断使用及び治療使用 |
JP2007514163A (ja) * | 2003-12-12 | 2007-05-31 | スリーエム イノベイティブ プロパティズ カンパニー | 可変性バルブ装置および方法 |
JP2011013237A (ja) * | 2003-12-12 | 2011-01-20 | Three M Innovative Properties Co | 可変性バルブ装置および方法 |
JP4673318B2 (ja) * | 2003-12-12 | 2011-04-20 | スリーエム イノベイティブ プロパティズ カンパニー | 可変性バルブ装置および方法 |
Also Published As
Publication number | Publication date |
---|---|
WO1995030004A1 (en) | 1995-11-09 |
EP0801679A1 (en) | 1997-10-22 |
CN1152939A (zh) | 1997-06-25 |
ES2238073T3 (es) | 2005-08-16 |
ATE290597T1 (de) | 2005-03-15 |
CA2188919C (en) | 2010-04-06 |
US5591629A (en) | 1997-01-07 |
KR100406551B1 (ko) | 2004-05-20 |
EP0801679B1 (en) | 2005-03-09 |
AU2399095A (en) | 1995-11-29 |
MX9605257A (es) | 1997-09-30 |
DE69534064D1 (de) | 2005-04-14 |
NZ284757A (en) | 1997-07-27 |
CA2188919A1 (en) | 1995-11-09 |
JP3789472B2 (ja) | 2006-06-21 |
KR970702918A (ko) | 1997-06-10 |
AU699724B2 (en) | 1998-12-10 |
DE69534064T2 (de) | 2006-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Miller et al. | Monoclonal autoantibodies promote central nervous system repair in an animal model of multiple sclerosis | |
JPH10503479A (ja) | 中枢神経系ミエリン再形成を促進するモノクローナル抗体 | |
US10351620B2 (en) | Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system | |
Pujol-Borrell et al. | Lectin-induced expression of DR antigen on human cultured follicular thyroid cells | |
JP5795753B2 (ja) | 髄鞘再形成を誘導する能力を有するヒトIgM抗体、および、特に中枢神経系における、その診断使用及び治療使用 | |
Kincade et al. | Development and distribution of immunoglobulin-containing cells in the chicken: an immunofluorescent analysis using purified antibodies to µ, γ and light chains | |
Dugich‐Djordjevic et al. | Immunohistochemical visualization of brain‐derived neurotrophic factor in the rat brain | |
US5574009A (en) | Method of stimulating myelination of cells | |
US20060140930A1 (en) | Promotion of central nervous system remyelination using monoclonal autoantibodies | |
Rose | Pathogenic mechanisms in autoimmune diseases | |
Barald | Monoclonal antibodies made to chick mesencephalic neural crest cells and to ciliary ganglion neurons identify a common antigen on the neurons and a neural crest subpopulation | |
JPS6344895A (ja) | 抗アミロイドa蛋白質単クロ−ン性抗体 | |
Franko et al. | Monoclonal antibodies to central nervous system antigens | |
EP0378572A1 (en) | HUMAN ANTI-Rh(D) MONOCLONAL ANTIBODIES | |
US20020164325A1 (en) | Promotion of central nervous system remyelination using monoclonal autoantibodies | |
MXPA96005257A (en) | Monoclonal antibodies that promote remayelination of the nervous cent system | |
Williams et al. | Cell-surface antigens of developing rat cerebellar neurons: identification with monoclonal antibodies | |
JPH03505668A (ja) | Gp48に対する特異抗体 | |
JPS6319562A (ja) | 抗ラフオ−ラ小体単クロ−ン性抗体 | |
Scolding et al. | Interactions between Oligodendrocytes and Complement | |
Smyrnis | The generation of monoclonal antibodies to neural cell type-specific antigenic determinants |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20041102 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050202 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050318 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050502 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050628 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050928 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20051114 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051226 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20060307 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20060329 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100407 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110407 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120407 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120407 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130407 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130407 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140407 Year of fee payment: 8 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |